S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
NYSE:MYOV

Myovant Sciences Stock Forecast, Price & News

$13.19
-0.31 (-2.30%)
(As of 01/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$12.33
$13.50
50-Day Range
$13.50
$21.39
52-Week Range
$12.33
$27.43
Volume
1.31 million shs
Average Volume
864,731 shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.74
30 days | 90 days | 365 days | Advanced Chart
Receive MYOV News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.


Myovant Sciences logo

About Myovant Sciences

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM (relugolix), a oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:MYOV
Fax
N/A
Employees
407
Year Founded
N/A

Sales & Book Value

Annual Sales
$59.32 million
Book Value
($3.90) per share

Profitability

Net Income
$-255.13 million
Net Margins
-164.51%
Pretax Margin
-164.13%

Debt

Price-To-Earnings

Miscellaneous

Free Float
88,550,000
Market Cap
$1.23 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
10/26/2021
Today
1/24/2022
Next Earnings (Confirmed)
1/26/2022
Fiscal Year End
3/31/2022

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

839th out of 1,415 stocks

Pharmaceutical Preparations Industry

403rd out of 683 stocks

Analyst Opinion: 3.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

Is Myovant Sciences a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Myovant Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOV, but not buy additional shares or sell existing shares.
View analyst ratings for Myovant Sciences
or view top-rated stocks.

How has Myovant Sciences' stock been impacted by COVID-19 (Coronavirus)?

Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MYOV stock has increased by 51.6% and is now trading at $13.19.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Myovant Sciences?

Myovant Sciences saw a increase in short interest in December. As of December 15th, there was short interest totaling 4,950,000 shares, an increase of 31.3% from the November 30th total of 3,770,000 shares. Based on an average daily trading volume, of 625,600 shares, the days-to-cover ratio is currently 7.9 days. Approximately 12.2% of the company's stock are short sold.
View Myovant Sciences' Short Interest
.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, January 26th 2022.
View our earnings forecast for Myovant Sciences
.

How can I listen to Myovant Sciences' earnings call?

Myovant Sciences will be holding an earnings conference call on Wednesday, January 26th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) posted its earnings results on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.11. The company had revenue of $77.90 million for the quarter, compared to analyst estimates of $72.67 million. During the same quarter in the prior year, the firm posted ($0.75) EPS.
View Myovant Sciences' earnings history
.

What price target have analysts set for MYOV?

5 Wall Street analysts have issued 1-year price objectives for Myovant Sciences' shares. Their forecasts range from $18.00 to $32.00. On average, they expect Myovant Sciences' stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 80.1% from the stock's current price.
View analysts' price targets for Myovant Sciences
or view top-rated stocks among Wall Street analysts.

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the following people:
  • David C. Marek, Chief Executive Officer & Director (LinkedIn Profile)
  • Jeffrey D. Nornhold, Senior VP-Pharmaceutical Operations & Development
  • Uneek Mehra, Chief Financial & Business Officer
  • Juan Camilo Arjona Ferreira, Chief Medical Officer
  • Matthew Lang, Secretary, Chief Administrative & Legal Officer (LinkedIn Profile)

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.01%). Company insiders that own Myovant Sciences stock include Chemical Co Ltd Sumitomo, David C Marek, Ferreira Juan Camilo Arjona, Frank Karbe and Matthew Lang.
View institutional ownership trends for Myovant Sciences
.

Which institutional investors are selling Myovant Sciences stock?

MYOV stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have sold Myovant Sciences company stock in the last year include David C Marek, Ferreira Juan Camilo Arjona, Frank Karbe, and Matthew Lang.
View insider buying and selling activity for Myovant Sciences
or view top insider-selling stocks.

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $13.19.

How much money does Myovant Sciences make?

Myovant Sciences has a market capitalization of $1.23 billion and generates $59.32 million in revenue each year. The company earns $-255.13 million in net income (profit) each year or ($2.61) on an earnings per share basis.

How many employees does Myovant Sciences have?

Myovant Sciences employs 407 workers across the globe.

What is Myovant Sciences' official website?

The official website for Myovant Sciences is www.myovant.com.

Where are Myovant Sciences' headquarters?

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 442074003351 or via email at [email protected].


This page was last updated on 1/24/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.